CONTROLLED-RELEASE IMPLANTS OF DISULFIRAM METABOLITES

Information

  • Research Project
  • 2044972
  • ApplicationId
    2044972
  • Core Project Number
    R44AA008961
  • Full Project Number
    2R44AA008961-02
  • Serial Number
    8961
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/1993 - 31 years ago
  • Project End Date
    7/31/1995 - 29 years ago
  • Program Officer Name
  • Budget Start Date
    8/1/1993 - 31 years ago
  • Budget End Date
    7/31/1994 - 30 years ago
  • Fiscal Year
    1993
  • Support Year
    2
  • Suffix
  • Award Notice Date
    7/30/1993 - 31 years ago
Organizations

CONTROLLED-RELEASE IMPLANTS OF DISULFIRAM METABOLITES

The goal of this program is to develop a bioerodible, controlled-release implant for the treatment of alcoholism. Specific Phase II aims are 1) to determine essential in vivo characteristics of a potent metabolite of disulfiram, 5-methyl N,N-diethylthiolcarbamate sulfoxide (DETC-MeSO); 2) to develop candidate bioerodible implants to deliver that metabolite; and 3) to test the efficacy of those candidate implants in rats. The dose- response characteristics, toxicity, and basic pharmacokinetics of DETC- Meso will be determined to identify the target performance of the implants. A series of bioerodible beads will be prepared, and their controlled-release and biodegradation characteristics determined. Candidate beads will then be implanted into rats for in vivo determination of efficacy via inhibition of aldehyde dehydrogenase. The use of bioerodible implants should greatly improve patient compliance in alcoholism programs. The use of DETC-MeSO, which is much more potent than disulfiram, should enable reasonably small implants to be effective, and it is also expected to be a more effective drug than disulfiram. Substantial commercial interest in this technology for treatment of alcoholism is expected if the results of this program are successful, and the technology may also be useful for other types of drugs, such as narcotic antagonists and chemotherapeutic agents.

IC Name
NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
  • Activity
    R44
  • Administering IC
    AA
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    273
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SRCA
  • Study Section Name
  • Organization Name
    BEND RESEARCH, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BEND
  • Organization State
    OR
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    977018583
  • Organization District
    UNITED STATES